Trial intelligence / Profile preview

Esketamine for early postoperative mood after laparoscopic total hysterectomy

ChiCTR2100049994Phase 4Recruiting

Sponsor
Hefei Second People's Hospital
Start
Aug 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial of esketamine in anxiety disorder, major depressive disorder (MDD), postoperative pain and 1 more (2 arms), sponsored by Hefei Second People's Hospital. Primary endpoints: Duration of anesthesia, surgery and orientation, Visual Analogue Score (VAS) and 5 more. Started Aug 2021; status: recruiting.

02

Drugs

esketamine
03

Conditions

anxiety disordermajor depressive disorder (MDD)postoperative painneurobehavioral conditions

Beyond the preview

Go deeper on ChiCTR2100049994.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100049994.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call